Ascendis Pharma presents TransCon PTH Data at ATA annual meeting

Ascendis Pharma presented a poster with results of a sub-analysis of its Phase 3 PaTHway clinical trial data during the recent American Thyroid Association, ATA, annual meeting, showing that 81% of adults with chronic post-surgical hypoparathyroidism treated with TransCon PTH achieved independence from conventional calcium and active vitamin D therapy while maintaining normal serum calcium levels during the 26-week blinded portion of the trial, compared to 6% taking placebo. The results were comparable to those from the overall PaTHway Trial population, which demonstrated consistency in improved outcomes with TransCon PTH treatment compared to conventional therapy across disease etiologies. “We are pleased to share with thyroid surgeons and thyroidologists attending ATA this data demonstrating the safety and benefits of TransCon PTH seen in clinical trial patients whose disease arose following neck surgeries,” said Aimee Shu, M.D., Vice President of Clinical Development, Endocrinology Medical Sciences at Ascendis Pharma. “Our goal is to provide a treatment option that can help patients overcome the serious health and quality of life burdens associated with hypoparathyroidism, regardless of its cause. We will continue to advance TransCon PTH globally as a candidate to address the urgent needs of this patient community.”